{"disease":{"id":"hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation","name":"hormone receptor positive her2 negative breast cancer with a pik3ca mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04967248","title":"A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting","phase":"","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}